Search for Terms or Answers
ACR Research Highlights Pediatric Treatment Gaps, Criteria Performance, and Early Promise of CAR T-Cell Therapy New research presented at ACR Convergence 2026 examines pediatric patient’s symptoms and potential therapies that can assist children and adolescents with symptom https://t.co/AZT1bFaoEm
Ab#1823 #ACR26 @RheumNow REGENCY, Furie OBI in LN: Wk76- OBI complete renal remiss (CRR) 46 v PBO 33% Non-CRR w proteinuria: Fail v damage? OBI - complete histologic remission, depleted B cells Histo remiss 47% v 19% PBO Suggests more impr outcomes in LN beyond endpt CRR #ACRBest https://t.co/qWv1KYxBXT
ALLO-329: CAR-T targeting not just CD19, but also CD70 (on host lymphocytes activated to attack donor cells) i.e. active anti-rejection mechanism so can give it without lymphodepletion B cells dip only modestly, transiently yet therapy seems to stick! ABST1178 #ACR26 @RheumNow https://t.co/9sksJGM45e
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.